Related Experiment Video
Updated: Jun 12, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Psoriasis care: new and emerging pharmacologic trends
1Probity Medical Research, Waterloo, ON. kapapp@probitymedical.com
Journal of Cutaneous Medicine and Surgery
|May 22, 2010
Summary
New psoriasis treatments are emerging in Canada, including ustekinumab for moderate to severe plaque psoriasis. The evolving landscape emphasizes patient-centered care and quality of life, simplifying treatment choices for physicians.
Area of Science:
- Dermatology
- Pharmacology
Background:
- The first Canadian Guidelines for Plaque Psoriasis management were recently published.
- These guidelines emphasize evidence-based analysis and patient-centered care for psoriasis therapies.
- Physicians are encouraged to find safe, effective, and satisfactory long-term treatment options for patients.
Purpose of the Study:
- To update the existing guidelines with new and emerging therapies for psoriasis.
- To discuss current trends in psoriasis clinical research.
Main Methods:
- Searches of Medline and clinicaltrials.gov were conducted.
- The searches identified new and emerging psoriasis therapies as of March 2009.
Main Results:
- Ustekinumab has been approved for moderate to severe psoriasis since May 2008.
- New formulations and combinations of existing psoriasis drugs are anticipated.
- Novel therapeutic agents are progressing through clinical development.
Conclusions:
- The psoriasis treatment landscape in Canada is dynamic, with new therapies introduced and others removed.
- Increased head-to-head treatment comparisons and ambitious outcome reporting will aid physician decision-making.
- Prioritizing quality of life in psoriasis treatment aligns with patient-centered care principles.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...